EyeGate Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Kiora Pharmaceuticals

13/05/2021 01:40

* EyeGate Pharmaceuticals Inc  EYEG.OQ  reported a quarterly
adjusted loss of 37 cents​​ per share for the quarter ended
in March. The mean expectation of two analysts for the quarter
was for a loss of 38 cents per share.
* Reported revenue was zero​;  analysts expected zero. 
* EyeGate Pharmaceuticals Inc's reported EPS for the quarter was
a loss of 37 cents​.
* The mean earnings estimate of analysts had risen by
about 17.2% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* EyeGate Pharmaceuticals Inc shares had fallen by 19.3% this
quarter and lost 18.5% so far this year.
* The company reported a quarterly loss of $2.58 million.
* Wall Street's median 12-month price target for EyeGate
Pharmaceuticals Inc is $12.13 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated May 13 at 12:40 a.m. GMT.
​All figures in US dollars